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Abbreviations used
BM: Bone marrow
CB: Cord blood
IgH: Immunoglobulin heavy chain
IGHC: Immunoglobulin heavy chain constant region
MBC: Memory B cell
PB: Peripheral blood
PC: Plasma cell
RT: Room temperature
sm: Surface membrane
SSC: Side scatter
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2 BLANCO ET ALBackground: Humoral immunocompetence develops stepwise
throughout life and contributes to individual susceptibility to
infection, immunodeficiency, autoimmunity, and neoplasia.
Immunoglobulin heavy chain (IgH) isotype serum levels can
partly explain such age-related differences, but their
relationship with the IgH isotype distribution within memory B-
cell (MBC) and plasma cell (PCs) compartments remains to be
investigated.
Objective: We studied the age-related distribution of MBCs and
PCs expressing different IgH isotypes in addition to the
immature/transitional and naive B-cell compartments.
Methods: B-cell and PC subsets and plasma IgH isotype levels
were studied in cord blood (n 5 19) and peripheral blood
(n 5 215) from healthy donors aged 0 to 90 years by using flow
cytometry and nephelometry, respectively.
Results: IgH-switched MBCs expressing IgG1, IgG2, IgG3, IgA1,
and IgA2 were already detected in cord blood and newborns at
very low counts, whereas CD271IgM11IgD1 MBCs only
became detectable at 1 to 5 months and remained stable until 2
to 4 years, and IgD MBCs peaked at 2 to 4 years, with both
populations decreasing thereafter. MBCs expressing IgH
isotypes of the second immunoglobulin heavy chain constant
region (IGHC) gene block (IgG1, IgG3, and IgA1) peaked later
during childhood (2-4 years), whereas MBCs expressing third
IGHC gene block immunoglobulin isotypes (IgG2, IgG4, and
IgA2) reached maximum values during adulthood. PCs were
already detected in newborns, increasing in number until 6 to
11 months for IgM, IgG1, IgG2, IgG3, IgA1, and IgA2; until 2 to
4 years for IgD; and until 5 to 9 years for IgG4 and decreasing
thereafter. For most IgH isotypes (except IgD and IgG4),
maximum plasma levels were reached after PC and MBC
counts peaked.
Conclusions: PC counts reach maximum values early in life,
followed by MBC counts and plasma IgH isotypes. Importantly,
IgH isotypes from different IGHC gene blocks show different
patterns, probably reflecting consecutive cycles of IgH isotype
switch recombination through life. (J Allergy Clin Immunol
2018;nnn:nnn-nnn.)
Key words: Immunoglobulins, IgH isotype, subclass, memory B
cells, plasma cells, flow cytometry, reference ranges, normal B cells,
age-related values
Serum immunoglobulin levels are widely accepted as the most
reliable surrogate marker for B-cell functionality in healthy
donors and patients with different immune-related diseases.1-6
Thus, reference serum immunoglobulin values per age group
have been generally adopted as the measure of changes in
B-cell immunocompetence through life.7-17
Overall, increasing serum immunoglobulin levels are observed
with age, although patterns vary for the distinct immunoglobulin
heavy chain (IgH) isotypes and subclasses. At birth, serum
contains low IgM and IgA levels, whereas maternal immuno-
globulinmolecules provide near-adult levels of serum IgG.13-15,18
Once maternal antibodies are cleared, the infant’s antibody re-
sponses are initially dominated by IgM, and serum IgM, IgG,
and IgA values reach approximately 100%, 60%, and 30% of
adult levels by the first year of life, respectively.14,15 Total serum
IgG levels gradually increase at early ages; however, different
production patterns are observed for the 4 IgG subclasses.16,17Although IgG3 and IgG1 levels increase faster and reach adult-
like concentrations at 5 to 10 years of age, IgG2 production is
delayed, with maximum levels at adulthood.16,17 Similarly, pro-
duction of IgG4 appears to be delayed, but reference values per
age group vary significantly among healthy subjects.16,17 Further-
more, both IgA1 and IgA2 levels increase gradually during child-
hood,8,19,20 reaching maximum IgA1 production around the
second decade of life, whereas IgA2 serum levels keep increasing
throughout adulthood.12 Finally, IgE serum levels peak around
10 years and decrease thereafter to adult levels.21 A common
feature for all serum IgH isotype subclasses (except for IgD,
IgG4, and IgE) is that their levels accumulate with
age.7,8,11,12,16 Once maximum levels are reached, serum IgH iso-
type subclass levels remain remarkably stable, without significant
changes in older subjects.18
In contrast to serum immunoglobulin levels, more dynamic
changes have been observed for total B-cell numbers and the
composition of the B-cell compartment in peripheral blood (PB).
Early studies reported that total B-cell counts increase 2-fold
immediately after birth, remain high until 2 years, and gradually
decrease approximately 6.5-fold until adulthood.22 Detailed im-
munophenotypic analyses demonstrated that the initial increase
is mostly due to an increased B-cell production in bone marrow
(BM) and release of high numbers of immature/transitional and
naive B cells into PB, with maximum values at 0 to 12 months
of age.23,24 This early wave of recently produced B cells is fol-
lowed by increased numbers of memory B cells (MBCs) that
rapidly increase from 2 months of life, remain high until age
5 years, and gradually decrease thereafter to adult-like
values.23-26 During adulthood, the number of immature/transi-
tional and naive B cells remains stable, whereas MBC and newly
generated plasma cell (PC) counts gradually decrease in subjects
older than 60 years.27,28
Thus far, accurate and robust detection of low PC counts in PB
(eg, in infants) appeared to be a challenge,23,25,26 and information
on IgH isotypes and subclasses within MBC and PC subsets re-
mains limited,27 with absence of age-related reference values.
Likewise, recent studies on antigen-experienced B cells express-
ing different IgH isotypes did not discriminate between MBCs
and PCs25 and/or did not provide data about the IgG1 to IgG4
and IgA1 and IgA2 subclasses.
24,26,27
Here we dissected the PB compartments of MBCs and PCs
into 38 distinct subsets expressing different IgH isotypes and
their subclasses and investigated their distribution in a large
series of normal cord blood (CB) and PB from healthy
European donors aged 0 to 90 years. Our ultimate goal was
to define the kinetics of the different B-cell and PC subsets
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subclass levels.METHODS
Samples
EDTA-anticoagulated CB (n 5 19) and PB samples from 215 healthy
European Caucasian donors (aged 0-90 years) with no past history of
immunologic or hematologic diseases (including allergy) were studied:
newborns (<12 days; 14 cases); children aged 1 to 5 months (11 cases), 6 to
11 months (7 cases), 12 to 17 months (12 cases), 18 to 23 months (12 cases), 2
to 4 years (25 cases), 5 to 9 years (22 cases), and 10 to 17 years (14 cases); and
adults aged 18 to 39 years (32 cases), 40 to 59 years (27 cases), 60 to 79 years
(27 cases), and greater than 80 years (12 cases). All samples were collected
after informed consent was provided by the subjects, their legal representa-
tives, or both, according to the Declaration of Helsinki. The study was
approved by the local ethics committees of the participating centers
(University of Salamanca, Salamanca, Spain; Charles University, Prague,
Czech Republic; University of Lisbon, Lisbon, Portugal; and La Paz Hospital,
Madrid, Spain).
All subjects were vaccinated following similar national vaccination
schedules (European Centre for Disease Prevention and Control; http://
vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx). CB was from Spain,
Portugal, and the Czech Republic, newborns and children aged 1 to 23 months
were from Spain and the Czech Republic, and all cases older than 2 years were
fromSpain. Donors with any sign or suspicion of immunologic or hematologic
diseases (including an abnormal infection rate or a known history of allergies)
were excluded from the study. In addition, a questionnaire with environmental
factors that could potentially affect development of the immune system,25,29,30
was conducted in children less than 4 years of age (n 5 36), with no differ-
ences observed in the frequency of these factors among the age groups evalu-
ated (see Table E1 in this article’s Online Repository at www.jacionline.org).
Also, the exact dates of different vaccinations receivedwere collected in a sub-
set of 72 children. Elderly donors (>80 years) were representative of a broader
group of elderly persons in the Salamanca region (median life expectancy, 82
and 87 years for men and women, respectively).Multiparameter flow cytometric identification of B
cells and their maturation-associated and
immunoglobulin isotype subclass subsets
Samples were processedwithin less than 24 hours after collection; 107 cells
per sample were stained with the EuroFlow 12-color IgH-isotype B-cell tube
(see Table E2 in this article’s Online Repository at www.jacionline.org). IgH
isotypes and subclasses were assessed in every sample by using surface mem-
brane staining; in addition, in a subset of 6 children (age, 3 6 5 years) and 6
adults (age, 33 6 8 years) surface membrane plus cytoplasmic staining was
done in parallel.
Both protocols were performed strictly according to the EuroFlow
BulkLysis standard operating procedure, as previously described (a detailed
protocol is provided in the Methods section in this article’s Online Repository
at www.jacionline.org and www.EuroFlow.org).31,32 A minimum of 5 3 106
leukocytes (including >_105 B cells) was acquired per tube with Fortessa
X-20 or LSR II Flow Cytometers (BD Biosciences, San Jose, Calif), and
FACSDiva software (BD Biosciences) was used. Instrument setup was stan-
dardized across laboratories according to the EuroFlow standard operating
procedure33 adapted for 12-color measurements. For data analysis, Infinicyt
software (Cytognos, Salamanca, Spain) was used. Absolute counts were
calculated by using a dual-platform assay.34Analysis of plasma IgH isotype subclass levels
Plasma from 18 CB and 201 PB samples from all age groups was obtained
by means of sequential centrifugation of PB (800g for 10 minutes) and
platelet-rich plasma (2000g for 5 minutes) and immediately stored at
2808C until analysis. Soluble IgM, IgE, and IgG1 to IgG4 subclass levelswere measured by using conventional nephelometry (Dimension Vista;
Siemens Healthcare, Erlanger, Germany), whereas IgA1, IgA2, and IgD
levels were measured by using the SPAPLUS turbidimetric system (Binding
Site, Birmingham, United Kingdom). For samples with IgH isotype subclass
concentrations of greater than the measurable range, appropriate dilutions
were made.Statistical analyses
To assess statistical significance (set at P <.05) of differences observed be-
tween distinct age groups, Mann-Whitney U and Wilcoxon tests for unpaired
and paired (continuous) variables were used, respectively. For categorical var-
iables, the Fisher exact test was applied (SPSS software, version 23; IBM,
Armonk, NY).RESULTS
Identification of maturation and isotypic
subpopulations of PB B cells
Based on their staining pattern for CD19, CD27, CD38, CD5,
CD24,CD21, surfacemembrane (sm) IgM, smIgD, and side scatter
(SSC), B cells (CD191SSClo/int forward scatterlo/int lymphocytes)
were classified into maturation-associated subsets (Fig 1, A and
B, and see Fig E1 in this article’s Online Repository at www.
jacionline.org).27,35 First, PCs were defined by a
CD3811CD271CD242CD212CD52CD19loSSCint phenotype.
Then pre–germinal center B cells were identified by their unique
CD272smIgM1smIgD1CD5het features; this subset was subdi-
vided subsequently into immature/transitional CD38hi
CD24hismIgM11IgD1 B cells and CD382CD24hetsmIgM1
IgD11 naive B lymphocytes. Afterward, unswitched MBCs were
identified by their unique CD38loCD52CD271
smIgM11IgD1 phenotype, and switched MBCs were defined as
CD38loCD52smIgM2IgD2 B cells (see Fig E1). Despite CD10
being reported to identify immature/transitional B cells, the combi-
nation of markers used here has proved sufficient to discriminate
reproducibly between mature and immature B cells.27,36
MBCs and PCs were further subclassified according to their
smIgH phenotype into (1) smIgM11IgD1, smIgD1, smIgA1
1,
smIgA2
1, smIgG1
1, smIgG2
1, smIgG3
1, and smIgG4
1 MBCs
and (2) smIgM1, smIgD1, smIgA1
1, smIgA2
1, smIgG1
1,
smIgG2
1, smIgG3
1, and smIgG4
1 PCs, respectively (Fig 2, A
and B, and Fig 2, D and E). All subsets of naive cells and
MBCs were further subclassified according to CD21 expression,
and the subset of switched MBCs was also further subdivided
based on CD27 expression. Although a minor fraction of PCs
did not show smIgH, no statistically significant differences
were observed in the IgH isotype and subclass distribution of
PCs when staining for smIgH was compared with cytoplasmic
IgH, either in children (n 5 6) or adults (n 5 6), except for the
percentage of IgH2 PCs, which was lower when cytoplamsic
versus Sm staining was used (see Fig E2 in this article’s Online
Repository at www.jacionline.org), which is in line with previous
findings.32Kinetics of total B cells and maturation-associated
B-cell subsets through life
Total lymphocyte andB-cell counts reachedmaximum levels at
approximately 1 to 5 months of age. The total lymphocyte count
increased progressively from CB to newborns and 1- to 5-month-
old children, whereas B cells showed a slightly delayed
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FIG 1. Age distribution of PB lymphocytes, total B cells, and maturation-associated B-cell subsets. A, Dot
plot representation of total lymphocytes (blue) and B cells (light orange). B, Three-dimensional Automated
Population Separator (APS) view: principal component 1 versus principal component 2 versus principal
component 3. Graphic representation of the B-cell maturation–associated subsets is shown as follows:
immature/transitional (green), naive (pink), and MBCs (orange), and PCs (violet). The APS representation,
which generates automatic separation of clusters of cells based on their immunophenotype, was used as
a visualization tool. The gating strategy is described in Fig E1. C-H, Absolute counts (cells per microliter)
of lymphocytes (Fig 1, C), total B cells (Fig 1, D), and maturation-associated B-cell subsets (Fig 1, E-H) pre-
sent in CB and PB distributed by age. Notched boxes represent 25th and 75th percentile values;middle line
corresponds to median values, and vertical lines represent the highest and lowest values that are neither
outliers nor extreme values. I, Lines link median values of total lymphocytes; total B cells, immature/transi-
tional naiveMBCs, and PCs. *P < .05, #P < .01, and §P < .001 versus the previous age group, respectively.NB,
Newborn.
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4 BLANCO ET ALsignificant increase during this period (P >.05 for CB vs for new-
borns; P 5 .001 for newborns vs 1- to 5-month-old children).
Thereafter, absolute B-cell counts progressively decreased until
adulthood (18 years), remaining relatively stable afterward(Fig 1, C, D, and I, and see Table E3 in this article’s Online
Repository at www.jacionline.org).
Most CB B cells corresponded to immature/transitional and
naive B cells (Fig 1, E, F, and I, and see Table E3). Still, a minor
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FIG 2. Distribution of different IgH isotype and subclass subsets of PB MBCs and PCs by age. A and D, Dot
plot graphic representation of MBC (Fig 2, A) and PC (Fig 2, D) subsets expressing distinct smIgH isotypes
and isotype subclasses: IgM(D1) (violet), IgG1 (light blue), IgG2 (light green), IgG3 (dark blue), IgG4 (dark
green), IgA1 (orange), IgA2 (yellow), and IgD (brown); smIgH
2 B cells are highlighted in gray. B and E,
Three-dimensional Automated Population Separator (APS) view: principal component 1 versus principal
component 2 vs principal component 3 of the IgH isotype and subclass subsets of MBCs (Fig 2, B) and
PCs (Fig 2, E) identified by the same color code as described above. The APS graphic representation, which
generates automatic separation of clusters of cells based on their immunophenotype, was used as a visu-
alization tool. C and F, Relative distribution of the distinct IgH isotype and subclass subsets ofMBCs and PCs
in the different age groups analyzed. *P < .05, #P < .01, and §P < .001 versus the previous age group, respec-
tively. NB, Newborn.
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BLANCO ET AL 5fraction of IgH-switchedMBCs was detected in most CB (95% of
subjects) in the absence of PCs (<_0.01 PCs/mL; Fig 1,G-I, and see
Table E3). Interestingly, although no significant differences were
observed in immature/transitional, naive, and MBC numbers be-
tween CB and newborn samples, PCs became detectable at low
numbers in most newborns (P < .001). Through life, the number
of PB immature/transitional and naive B cells showed a similar
profile to that of total B cells, with a peak at 1 to 11 months
(P <_ .001 vs CB) and a progressively significant decrease until
adulthood (P <.001 vs 18- to 39-year-old subjects). Subjects older
than 18 years showed relatively stable numbers of both immature/
transitional and naive B cells (Fig 1,E,F, and I, and see Table E3).
MBC and PC counts increased from CB and newborn samples
to 1- to 5-month-old children (P <_.001). PC counts already started
to decrease in children older than 23 months (P 5 .03), with agradually continued decrease through adulthood. In contrast,
MBC counts increased gradually until age 2 to 4 years
(P < .001 vs 1- to 5-month-old children) followed by a decrease
until a plateau was reached that lasted through adolescence (10-
17 years) until adulthood (40-59 years); afterward, MBC counts
progressively decreased (P 5 .02 vs >80 years; Fig 1, G and H,
and see Table E3).Age distribution of MBCs expressing distinct IgH
isotypes and subclasses
Relative and absolute counts of MBCs expressing different
IgH isotypes and subclasses varied significantly through life
(Figs 2 and 3). smIgM11IgD1 MBCs represented the largest
fraction of MBCs (approximately 80%) in 1- to 5-month-old
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6 BLANCO ET ALchildren, being significantly expanded versus those in CB and
newborns (P < .001), with a subsequent decrease to 40% to
50% of MBCs. Conversely, smIgG1
1, smIgG3
1, and smIgA1
1
switched MBCs showed a transient relative decrease among 1-
to 5-month-old children versus newborns (P <_.01), with their rela-
tive numbers increasing significantly at 6 to 11 months until 2 to
4 years for smIgG1
1 (P 5 .001 for 6-11 months vs 1-5 and 2-
4 years vs 18-23 months) and at 5 to 9 years for smIgG3
1
(P 5 .02), when they started to decrease, particularly in the tran-
sition to adulthood. In turn, the percentage of smIgA1
1 MBCs
increased progressively from 2 to 4 years until 10 to 17 years
(P 5 .003 for 2-4 years vs 5-9 years and P < .001 for 2-4 years
vs 10-17 years), remaining rather stable from then onward. In
contrast, both smIgG2
1 and smIgA2
1 MBCs reached their high-
est representation in young (18-39 years) adults (P <_.001). During
adulthood, no significant changes were observed in the relative
distribution of most IgH subsets of MBCs, with a few exceptions
(Fig 2, C).Regarding absolute counts, very low numbers of MBCs were
observed in CB and newborns, with similar frequencies of
subjects with detectable IgH subsets of MBCs (see Table E4 in
this article’s Online Repository at www.jacionline.org). Subse-
quently, nonswitched smIgM11IgD1 MBCs became detectable
at significantly increased counts among 1- to 5-month-old chil-
dren (P5.001), with numbers remaining fairly stable until 4 years
and subsequently decreasing significantly to adult levels at 10 to
17 years (P < .002, Fig 3). After 60 years, progressively lower
numbers of smIgM11IgD1 MBCs were observed (P 5 .002 for
40-59 years vs >80 years). The smIgD1IgM2 MBCs showed a
very similar profile: increased counts until 2 to 4 years of
age, which progressively decreased thereafter (Fig 3 and see
Table E4).
In contrast, MBCs expressing smIgG3, smIgG1, and smIgA1
(IgH isotype subclasses of the second immunoglobulin heavy
chain constant region [IGHC] gene block) showed progressively
higher counts until 2 to 4 years (P <_ .03) and remained relatively
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BLANCO ET AL 7stable until 10 to 17 years of age. Interestingly, although MBC
counts with smIgG2
1 and smIgA2
1 expression (IgH isotype sub-
classes of the third IGHC gene block) also increased in childhood,
these counts continued increasing until adulthood, with signifi-
cantly higher counts among 18- to 39-year-old adults versus
younger subjects (P 5 .03 and P 5 .005, respectively). Despite
representing a minor subset (<1% and <1 cell/mL for most do-
nors), particularly among children, smIgG4
1 MBCs peaked at
40 to 59 years (Fig 3 and see Table E4).
Interestingly, the immunophenotype of switched MBCs
differed significantly between CB/newborns versus older
children and adults. Thus although switched MBCs in CB
and newborns lacked CD27, most MBCs from children older
than 1 month and adults (80% to 90%) were CD271. The per-
centage of CD271smIgG3
1 MBCs also increased after the first
month (40% to 60%), but the fraction of CD272 cells re-
mained significantly greater (>_40%) in smIgG3
1 MBCs than
in MBCs with other IgH isotype subclasses (see Fig E3 in
this article’s Online Repository at www.jacionline.org). More-
over, although CB and newborn MBCs were mostly CD211, a
significantly higher proportion of CD212 switched MBCs was
observed among 1- to 11-month-old children versus all other
age groups. In contrast, the percentage of CD212 naive B lym-
phocytes and CD212 smIgM11IgD1 MBCs remained low and
relatively stable among all age groups. Similar to CD27, thepercentage of CD212 cells within smIgG3
1 MBCs was also
greater than among MBCs expressing other smIgH isotype
subclasses (see Fig E4 in this article’s Online Repository at
www.jacionline.org).Age distribution of PC subsets expressing different
IgH isotypes and subclasses
Despite their absence in normal CB, PCs were detected in most
newborn samples (79%) and in all childhood and adult PB
samples analyzed. In contrast to MBCs, PCs from newborns were
mostly IgM1 (68% to 96% of PCs), with only 7% to 25% of NBs
showing smIgG11 (range, 0% to 13%), smIgA1
1 (range, 0% to
6.8%), smIgG2
1 (range, 0% to 2.3%) and/or smIgA2
1 PCs
(range, 0% to 2.3%; Fig 2, F, and see Table E4).
Children at 1 to 5 months had greater percentages of
smIgG3
1, smIgG1
1, smIgA1
1, smIgG2
1, and smIgA2
1 PCs
than newborns (P <_ .003), whereas the proportion of smIgM1
PCs decreased at this age (P <_ .001). Thereafter, the relative dis-
tribution of circulating PCs expressing different IgH isotypes
and subclasses remained relatively stable, except for a transient
increase in IgA1
1 PC counts at 10 to 17 years, a decrease in
IgG3
1 PC counts in adults, and a progressive increment of
smIgG2
1 and smIgA2
1 cell counts until 10 to 17 and 18 to
39 years, respectively (Fig 2, F). Finally, the relative number
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8 BLANCO ET ALof smIgD1 and smIgG4
1 PCs was greater among 2- to 4-year-
old (P 5 .001) and 5- to 9-year-old children (P 5 .01), respec-
tively (Fig 2, F).
Regarding absolute counts, the number of PB smIgM1 PCs
increased significantly during the first year of life (P < .001).
Thereafter, smIgM1 PCs decreased gradually from 1 to 2 years
onward, reaching the lowest levels among adults older than
60 years. In contrast, IgD1 PC numbers peaked at 2 to 4 years,
progressively decreasing thereafter (Fig 4). Increased smIgG3
1
and smIgG1
1 PC counts were already detected among 1- to 5-
month-old children (P <_ .001). In turn, PCs expressing smIgA1,
smIgA2, and smIgG2 showed significantly increased counts
from newborns to 6- to 11-month-old children (P <_ .02). All
these IgH-switched PC subsets decreased gradually in the tran-
sition from late childhood to adulthood. Finally, smIgG4
1 PC
numbers peaked at 5 to 9 years, decreasing thereafter (Fig 4
and see Table E4).Plasma levels of distinct IgH isotypes and
subclasses through life
All IgG subclasses (IgG1-IgG4) were systematically detected
already in CB and newborn plasma. In contrast, IgM and IgA2
were detected in only a fraction of the CB (61% and 65% cases,
respectively) and newborn (60% and 10% cases, respectively)
plasma samples investigated; no IgA1 or IgD plasma levels of
greater than the limit of detection (>3.58 and >0.66 mg/dL,
respectively) were found in newborn samples, and IgA1 was
found in only 1 CB sample. Later, soluble IgM, IgA1, and IgA2
plasma levels became detectable systematically (except IgM in
1 donor) at higher levels among 1- to 5-month-old children
(P <_.004); IgA1 and IgA2 plasma levels gradually increased there-
after, whereas IgM plasma levels started to (slightly) decrease
among 40- to 59-year-old adults. IgD plasma levels remained
relatively stable through life until the age of 80 years. Regarding
J ALLERGY CLIN IMMUNOL
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and IgG4 (but not IgG3) levels, as well as total immunoglobulin
plasma levels, was observed during the first year of life, with
the levels of all IgG subclasses and total immunoglobulin levels
increasing thereafter until elderly age. Finally, IgE plasma levels
peaked at 10 to 17 years, remaining relatively stable thereafter
(Fig 5 and see Table E5 in this article’s Online Repository at
www.jacionline.org).DISCUSSION
Serum/plasma immunoglobulin levels have been used classi-
cally to define the ability (eg, protection against infection) or
inability (eg, immunodeficiency) of B cells to mount effective and
sustained immune responses. However, in recent years,
increasing evidence indicates that a subgroup of long-lived PCs
accumulate in the BM over years (or even decades) and are the
major contributor to immunoglobulin plasma levels.18,27,37More-
over, comparison of B-cell numbers and serum antibody levels in
infection models has shown that specificMBCs are more affected
by age than serum antibody levels.38 Therefore immunoglobulin
levels in plasma might not reflect the actual status of the B-cell
compartment in real time. Nevertheless, this hypothesis has not
been fully confirmed, and direct detailed evaluation of the
B-cell compartment through life has been only partially achieved.
Here we analyzed the distribution of 38 subsets of MBCs and
PCs, including those expressing different IgH isotype subclasses,
through life and their relationships with the corresponding IgH
plasma levels. Only IgEMBCs and PCs, identification of which in
PB of healthy (nonallergic) donors remains controversial,39-41
could not be studied because of the absence of reliable and sensi-
tive antibody reagents to detect them on the cell surface mem-
brane in healthy subjects at very low levels,32 despite several
anti-IgE clones being tested here for analyses that included
more than 100,000 B cells (data not shown).
In line with previous observations,42 increased production of
immature/transitional and naive B cells was observed during
the first year of life. Afterward, BM production decreased pro-
gressively until adulthood, when immature/transitional and naive
B-cell counts in PB stabilized. No further age-related differences
were observed when young versus elderly adults were compared,
as also reported by others.27
Although serologic studies in steady-state7-10,14-16,18 and
immunized43 subjects suggest that children have a lower ability
to produce PCs,44 direct quantification of circulating PCs
showed that PCs become detectable in newborns and are pro-
duced at massive levels in infants, when their PC counts are
10-fold greater than in young adults. Of note, no correlation
was observed between the number of PCs and the vaccination
schedule (data not shown), despite all infant but newborn sam-
ples were analyzed more than 8 days apart from the last
vaccine. These results suggest that previously used methods to
evaluate B-cell effector functions are probably biased by long-
lived BM PC immunoglobulin production, and flow cytometry
provides direct evaluation of the actual PC counts.28 In this re-
gard, circulating PCs are a very dynamic cell population with a
high turnover rate27,28 that might offer a closer view into
ongoing B-cell responses. In fact, our results indicate that PC
production precedes (the peak of) production of both MBCs
and serum immunoglobulin levels by years or even decades, de-
pending on the IgH isotype subclass evaluated (see Fig E5).In line with this, new preliminary observations from our group
indicate that the number of circulating normal PCs correlates with
hypogammaglobulinemia, risk of infection, and BM PC produc-
tion in both B-cell and PC neoplasms (Criado et al, unpublished
data; Sanoja-Flores et al45). Therefore evaluation of PC counts in
PB emerges as a surrogate marker for (future) PC production in
BM and potentially also an early predictor of primary antibody
deficiencies, particularly because the diagnosis of many primary
antibody deficiencies is currently delayed to children 4 years old
or older because of the slower constitution of antibody levels in
serum.46,47
Of note, massive PC production associated with early (first)
antigen stimulation of naive B cells does not translate into a
parallel increase in corresponding antibody serum levels. Thus
accumulation of long-lived PCs in BM, which are required to
produce significant antibody serum levels,might still be limited in
infants because of the intrinsic (pro)-apoptotic susceptibility of
newly generated PCs,27,28 the immaturity of the BM environment
after birth,48 and/or overfilling of BM by highly proliferating
B-cell precursors during childhood,42 which might occupy the
BM survival niches for PCs. In turn, when significant levels of
serum immunoglobulins are generated, decreased PC counts of
the corresponding IgH isotype were observed, probably because
of antibody-dependent modulation of B-cell responses.49,50 Inter-
estingly, immature/transitional and naive B-cell counts and IgH
plasma levels remained stable through adulthood, whereas the
number of PCs andMBCs decreased in the elderly versus younger
adults, which is in line with previous findings.27,28 The reduced
ability to produce antigen-experienced B cells might explain
why elderly subjects more frequently have severe infections and
a lower capacity to produce antigen-specific antibodies after
vaccination, despite having similar (even slightly higher) serum
antibody levels versus younger adults44,51-54
Overall, the observed kinetics of the sequential waves of PCs,
MBCs, and plasma IgH levels throughout life were influenced by
the relative position of the IgH isotype/subclass gene segments
within the IGHC locus. Thus IgG3 and IgG1 production peaks
appear to precede those of IgG2 and IgG4 for PCs (1-5 months
vs 6-11 months and 5-9 years), MBCs (2-4 years vs 18-39 years),
and serum antibody levels (5-9 years vs 18-39 years; see Fig E6 in
this article’s Online Repository at www.jacionline.org). Among
IgA subclasses, no age-related differences were observed for
the PC peaks (both detected in 6- to 11-month-old children),
which could be due to the fast rate of IgA responses induced by
massive gut bacterial colonization after birth.55 Nevertheless,
when IgA MBCs and IgA plasma levels were analyzed, we
confirmed that IgA1 MBC and serum IgA1 levels increased faster
than levels of their IgA2 counterparts (2-4 years vs 18-39 years
and 10-17 years vs 40-59 years, respectively). In line with these
findings, previous reports indicate that IgG2, IgG4, and IgA2
show a greater number of mutated sequences and greater levels
of antigen selection than IgG3, IgG1, and IgA1,
56,57 supporting
the notion that IgH isotypes encoded by the third block of the
IGHC locus might, at least in part, be generated by secondary
class-switch recombination events. Sequential production of
different IgH isotypes might also influence the pattern of B-cell
responses during life. Thus although IgH molecules from the first
and second IGHC gene blocks (IgM and IgG3, IgG1, and IgA1)
show a higher ability for complement binding, opsonization,
and triggering of natural killer cell–mediated cytotoxicity, those
from the third block of the IGHC locus (IgG2, IgG4, and IgA2)
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hold functional relevance, sequential production of distinct IgG
and IgA subclasses through life might lead to a more tolerogenic
response in adults versus children, with a potential for lower ex-
pansions of terminally switched MBCs with increasing age.
In addition to massive PC production during the first year of
life, vaccination does not mount a sustained immune response in
infants, particularly against encapsulated bacteria.44 This sug-
gests that the immaturity of the secondary B-cell response in in-
fants might be related not only to a lower number of circulating
MBCs but also to the ability of these MBCs to respond against
different stimulatory conditions. In fact, MBCs from CB, new-
borns, and infants less than 2 years of age showed significant
phenotypic differences to those of children older than 2 years
and adults; such differences involved functional markers poten-
tially associated with maturation of other cellular and soluble
components of the immune system. Thus in line with the absence
of organized germinal centers during fetal life and in new-
borns,61-63 the very few switched MBCs detected in CB and new-
borns lacked CD27, a molecule that has been previously
associated with T-dependent germinal center B-cell re-
sponses.35,64 Further expansion of CD271MBCs during the first
year of life occurred in parallel with an increased proportion of
CD212 (C3d receptor) MBCs with a limited ability to respond
to polysaccharide-complement complexes.65,66 The fact that
within naive B cells the percentage of CD212 cells remains stable
with age and shows a comparable in vitro response to polysaccha-
ride antigens in children and adults67 suggests that external fac-
tors affecting antigen recognition might increase the production
of C3d receptor–deficient MBCs in children of around 1 year of
age when serum C3 levels reach adult-like values.68 Thus the
limited availability of C3d and C3d-antigen complexes in infants
less than 1 year old because low serum C3 levels69 might
contribute to reduced signaling for expression of this receptor dur-
ing antigen recognition. In line with this, other age-related pheno-
typic subsets of MBCs have been previously reported, such as the
‘‘atypical’’ MBCs and the minor population of CD11c1 (iC3b re-
ceptor) B cells,70-72 which overlapped herewith CD212 cells both
in children and adults (see Fig E7 in this article’s Online Repos-
itory at www.jacionline.org), as well as in other studies.27
Although we did not confirm here in human subjects previous ob-
servations about the potential expansion of atypical
CD272CD212 MBCs or other CD212 subsets of B cells in
elderly subjects (see Fig E8 in this article’s Online Repository
at www.jacionline.org), there might be additional phenotypic
markers that might contribute to better understand B-cell immu-
nity at advanced ages.
Altogether, these results suggest that maturation of other
components of the immune response (eg, complement levels
and germinal centers in lymphoid tissues) potentially contribute
to determine the number of MBCs generated and their phenotype
and consequently also their functional abilities. However, the
effect of these environmental costimulatory signals might also be
influenced by the position of the IgH isotype in the IGHC gene
because, independent of age, a higher proportion of CD272 and
CD212 MBCs was observed among those B-cell compartments
expressing upstream IgH isotypes (eg, IgG3) versus those display-
ing IgH subclasses located at the end of the IGHC gene (eg, IgG2).
Overall, our results support the notion that despite serum IgH
levels possibly provide important information about the long-
lived steady-state PCs that accumulate in BM, they are not enoughto fully understand the humoral immunocompetence status of a
subject. PCs in PB emerge as a robust earlier sensor of actual
ongoing immune responses, whereas progressive accumulation of
MBCs expressing IgH isotypes and subclasses encoded by the
downstream part of the IGHC locus reflect potential terminal
sequential class-switching and accumulation ofMBCs expressing
more tolerogenic isotypes at more advanced ages, as also
confirmed by very preliminary data on longitudinal changes in
children (see Fig E9 in this article’s Online Repository at www.
jacionline.org). Additionally, we provide normal reference values
for PCs and MBCs expressing different IgH isotypes and sub-
classes that, once confirmed in larger longitudinal series of sub-
jects from different genetic and geographic backgrounds, might
be of value in future studies in patients with multiple disease con-
ditions, particularly immunodeficiency, inflammation, allergy,
autoimmunity, and infection.
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Sample preparation
Forty-eight milliliters of an ammonium chloride solution was mixed
with 2 mL of PB in a 50-mL tube and incubated for 15 minutes at room
temperature (RT) while gently shaking in a roller to lyse nonnucleated red
cells. Then the cell suspension was centrifuged for 10 minutes at 800g, and
the supernatant was removed by using a Pasteur pipette or a vacuum sys-
tem without disturbing the cell pellet. Thereafter, cells were washed with
50 mL of PBS containing 0.5% BSA and 0.09% sodium azide (PBS-BSA;
pH 7.6) and centrifuged at 800g for 5 minutes, and the supernatant was
removed. Subsequently, 4 mL of PBS plus 0.09% of NaN3 plus 0.5% of
BSA was added, and the cell suspension was transferred to a 5-mL tube,
which was centrifuged at 540g for 5 minutes. After removal of the super-
natant, sample cellularity was counted in a hematologic analyzer. Ten
million nucleated cells were stained subsequently with the 12-color Euro-
Flow antibody combination (30 minutes at RT). When only smIgH stain-
ing was performed, 2 mL of FACS lysing solution (BD Biosciences, San
Jose, Calif) diluted 1:10 (vol/vol) in distilled water was added, and cellswere sequentially incubated for another 10 minutes at RT, washed, and re-
suspended in 500 mL of PBS-BSA. In turn, when surface membrane plus
cytoplasmic IgH staining was performed, after surface membrane staining,
the cell suspension was washed and incubated with solution A of the Fix &
Perm Reagent Kit (An der Grub, Vienna, Austria) for 15 minutes at RT.
Afterward, washed cells were incubated for another 15 minutes at RT
with solution B of the Fix & Perm Reagent Kit and antibodies against
IgM, IgD, IgG1 to IgG4, and IgA1 and IgA2; then stained cells were
washed and resuspended in 500 mL of PBS-BSA. In both protocols cells
were acquired immediately after sample preparation was completed or
stored at 48C for a maximum of 1 hour.
CD11c staining
In 6 adults (35 6 8 years) and 6 children (3 6 5 years), in addition to the
EuroFlow 12-color IgH isotype B-cell tube (Table E2), a similar tube that con-
tained an anti-CD11c PE-Cy7 (clone B-ly6; BD) reagent instead of CD5 PE-
Cy7 was stained in parallel. The protocol used was the same as described
above, and 5 3 106 leukocytes were measured per sample.
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FIG E1. Gating strategy used for identification of maturation-associated B-cell subsets. Bivariate dot plot
graphic representations of the gating strategy used to identify immature, naive, switched, and unswitched
MBCs and PCs, according to their pattern of expression of CD19, CD27, CD38, CD5, CD24, CD21, smIgM, and
smIgD and their side-scatter (SSC) features are shown.
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FIG E2. Comparison of the relative distribution in PC of subsets expressing distinct IgH isotypes and
subclasses when surface membrane only versus surfacemembrane plus cytoplasmic staining of aliquots of
the same sample (n5 12) was performed. Bars represent relative distribution of the distinct IgH isotype and
subclass subsets of PCs with the sm-only versus surface membrane plus cytoplasmic IgH staining in chil-
dren (n5 6) and adults (n5 6). *P < .05, surface membrane only versus surface membrane plus cytoplasmic
staining.
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FIG E3. Relative distribution of CD272 B cells within each subset of CB and PB memory B lymphocytes ex-
pressing different IgH isotypes and isotype subclasses through life. Bars represent percentage values of
CD272 B cells within each MBC compartment. *P < .05, #P < .01, and §P < .001 versus the previous age
group, respectively. NB, Newborn.
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FIG E4. Relative distribution of CD212 B cells within each subset of CB and PB naive B lymphocytes and
MBCs expressing different IgH isotypes and isotype subclasses through life. Bars represent percentage
values of CD212 B cells within each B-cell compartment. *P < .05, #P < .01, and §P < .001 versus the previous
age group, respectively. NB, Newborn.
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uble levels of the same IgH isotype and isotype subclasses through life. Lines correspond to median abso-
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deciliter; red) per age group. LOD, Limit of detection; NB, newborn.
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ADULTCHILD
FIG E7. Pattern of expression of CD21 in CD11c1 in MBCs. Dot plots illus-
trating CD11c expression with MBCs of a representative healthy child and
a healthy adult are shown. In both types of samples, CD11c1MBCs system-
atically corresponded to CD212 MBCs in line with previous findings re-
ported in the literature.27,71
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FIG E8. Relative distribution of typical, atypical, and other CD212 B cells within each compartment of MBCs
expressing different IgH isotypes and subclasses through life. A, Representative dot plot of MBCs grouped
according to CD21 and CD27 expression. B, Bars represent percentage values of typical (CD271CD211),
atypical (CD272CD212), other CD212 B cells (CD271CD212) and CD272CD211 MBCs within each subset of
MBCs expressing different IgH isotypes and subclasses. *P < .05, #P < .01, and §P < .001 versus the previous
age group, respectively. NB, Newborn.
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FIG E9. t-Distributed stochastic neighbor embedding plots showing the relative size of different subsets of
MBCs and PCs expressing distinct IgH isotypes and subclasses in a single child at 2 different ages (23 and
41 months). Please note the relative decrease in, for example, IgG3 MBCs (A) and both IgM and IgG3 PCs at
the expense of a larger IgA1 and IgG1 PC area (B).
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TABLE E1. Demographics of children younger than 4 years included in the study
Environmental factors
Age group
0-5 mo 6-11 mo 12-17 mo 18-23 mo 2-4 y
Breast-feeding ever 80% 100% 71% 86% 92%
Breast-feeding until 6 mo — 60% 30% 50% 50%
Day care 20% 40% 71% 43% 83%
Pets 20% 20% 14% 0% 25%
Rural environment 0% 40% 43% 29% 17%
Smoking parents 60% 20% 14% 29% 25%
Smoking during pregnancy 20% 40% 14% 14% 17%
Delivery
Vaginal 100% 60% 86% 71% 92%
Caesarean 0% 20% 14% 29% 8%
Percentage of subjects analyzed presenting each environmental factor per age group.
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TABLE E2. EuroFlow 12- color IgH isotype B-cell tube
Fluorochrome
conjugated to
antibody
reagent BV421 BV510 BV711 BV650 BV786 FITC PerCP-Cy5.5 PE PE-CF594 PE-Cy7 APC APC-H7
Antibody
marker
CD27 smIgM CD21 CD24 CD19 smIgG3 1
smIgG2
smIgA1 1
smIgA2
smIgG1 1
smIgG2
smIgD CD5 smIgG4 1
smIgA1
CD38
Antibody
clone
M-T271 MHM-88 B-ly4 ML5 SJ25C1 SAG3/SAG2 SAA1/SAA2 SAG1/SAG2 IA6-2 L17F12 SAG4/SAA1 HB7
Antibody
manufacturer
BD Biosciences,
San Jose, Calif
BioLegend,
San Diego,
Calif
BD
Biosciences
BD
Biosciences
BD
Biosciences
Cytognos,
Salamanca,
Spain
Cytognos Cytognos BD
Biosciences
BD
Biosciences
Cytognos BD
Biosciences
Combination of fluorochrome-conjugated antibodies used for the immunophenotypic analysis of PB samples by flow cytometry.
APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin-chlorophyll-protein complex.
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TABLE E3. Absolute number of PB lymphocytes, total B cells, and maturation-associated B-cell subsets in healthy control subjects distributed per age group
CB (n 5 19) NB (n 5 14) 1-5 mo (n 5 11)
6-11 mo
(n 5 7)
12-17 mo
(n 5 12)
18-23 mo
(n 5 12)
2-4 y
(n 5 25)
5-9 y
(n 5 22)
10-17 y
(n 5 14)
18-39 y
(n 5 32)
40-59 y
(n 5 27)
60-79 y
(n 5 27)
>80 y
(n 5 12)
Lymphocytes 3,710
(2,041-5,687)
5,049
(2,581-8,360)
6,771
(2,443-9,955)
5,709
(5,150-8,531)
6,547
(4,611-9,924)
5,014
(3,798-11,033)
4,184
(1,620-6,856)
3,134
(1,967-4,564)
3,109
(1,749-3,739)
2,504
(1,479-3,681)
2,273
(1,280-3,192)
2,408
(1,531-4,891)
2,386
(938-2,793)
Total B cells 502
(313-1,280)
357
(108-1,322)
1533 (470-4,327) 1,294
(869-2,316)
1,186
(692-1,737)
965
(268-1,559)
825
(302-1,637)
451 (157-725) 360 (174-630) 220 (41-470) 148 (91-413) 173 (36-384) 141 (42-283)
Immature
B cells
116 (40-316) 65 (15-343) 449 (228-1,398) 268
(111-384)
157
(105-389)
120
(39-300)
108 (36-314) 41 (12-84) 37 (11-111) 5.6 (0.25-24) 6.0 (0.84-23) 6.1 (0.69-36) 5.7 (1.3-23)
Naive B cells 426 (214-962) 298 (71-976) 981 (186-2,620) 812
(508-1,686)
677
(232-1,293)
678
(181-1,254)
473
(204-1,064)
265 (68-505) 189 (75-401) 111 (13-288) 83 (26-244) 109 (20-280) 80 (15-210)
Memory
B cells
0.3 (<0.01-3.0) 0.4 (<0.01-2.3) 73 (20-283) 115
(48-219)
111
(79-291)
131
(44-241)
182 (48-343) 123 (64-282) 68 (31-160) 91 (23-221) 70 (25-173) 56 (13-128) 30 (8.1-119)
PCs <0.01 0.3 (<0.01-4.2) 21.2 (1.6-48) 53
(24-104)
28 (8.1-82) 43
(4.8-144)
18 (4.1-52) 13 (3.5-45) 8.5 (1.3-27) 4.4 (1.1-25) 2.7 (0.6-9.7) 1.2 (0.3-7.1) 1.5 (0.14-18)
Results are expressed as median number of cells per microliter (range).
NB, Newborn.
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TABLE E4. Percentage of cases with detectable numbers of PB MBCs and PCs expressing different IgH isotypes and isotype subclasses and their absolute numbers per age
group
CB
(n 5 19)
NB
(n 5 14)
1-5 mo
(n 5 11)
6-11 mo
(n 5 7)
12-17 mo
(n 5 12)
18-23 mo
(n 5 12)
2-4 y
(n 5 25)
5-9 y
(n 5 22)
10-17 y
(n 5 14)
18-39 y
(n 5 32)
40-59 y
(n 5 27)
60-79 y
(n 5 27)
>80 y
(n 5 12)
MBC subsets
IgMD1
Cases 0% 0% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL <0.01 <0.01 61 (8.6-245) 84 (21-170) 76 (45-186) 81 (31-153) 92 (24-207) 54 (23-147) 29 (17-78) 38 (7.9-122) 36 (12-114) 27
(7.4-72)
11 (2-56)
IgD1
Cases 0% 0% 9% 57% 50% 78% 96% 95% 79% 69% 57% 48% 25%
Cells/mL <0.01 <0.01 <0.01 0.1 (<0.01-1.4) 0.4
(<0.01-2.1)
0.4
(<0.01-5.6)
2.0 (<0.01-6.9) 1.1
(<0.01-2.9)
0.3
(<0.01-1.7)
0.2 (<0.01-2.4) 0.06
(<0.01-0.9)
0.01
(<0.01-1.2)
0.01
(<0.01-0.4)
IgG1
1
Cases 63% 86% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL 0.1
(<0.01-0.6)
0.2
(<0.01-0.8)
2.3 (0.1-13) 12.5 (6.9-28) 19 (11-65) 28 (6.9-69) 49 (11-130) 30 (12-86) 18 (7-42) 18 (3.2-40) 11 (2.8-30) 9.1 (1.3-22) 6.7 (2.0-31)
IgG2
1
Cases 37% 21% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL 0 (<0.01-0.2) 0.04
(<0.01-0.2)
0.3 (<0.01-1.2) 0.6 (0.4-3.5) 1.4 (0.5-3.4) 2.9 (0.6-6.1) 3.4 (0.8-11) 4.4 (0.7-15) 3.0 (0.7-10) 5.9 (1.6-30) 4.7 (0.6-14) 3.6 (1.0-11) 2.4 (0.4-12)
IgG3
1
Cases 74% 50% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL 0.06
(<0.01-0.7)
0.03
(<0.01-0.5)
0.9 (0.4-4.7) 2.8 (1.4-6.2) 4.3 (1.6-14) 5.5 (1.5-12) 6.0 (1.8-17) 7.4 (2.4-16) 3.0 (1.1-8.3) 3.0 (0.5-8.4) 2.1 (0.7-6.6) 2.3 (0.4-8.1) 2.0 (0.7-6.5)
IgG4
1
Cases 0% 0% 18% 71% 83% 92% 76% 86% 86% 91% 89% 92% 92%
Cells/mL <0.01 <0.01 <0.01
(<0.01-0.6)
0.07 (<0.01-0.4) 0.3
(<0.01-1.4)
0.1
(<0.01-0.5)
0.1
(<0.01-1.9)
0.4
(<0.01-2.0)
0.2
(<0.01-2.9)
0.4 (<0.01-2.4) 0.4
(<0.01-4.1)
0.4
(<0.01-2.1)
0.3
(<0.01-2.3)
IgA1
1
Cases 90% 79% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL 0.1
(<0.01-1.2)
0.1
(<0.01-1.1)
2.3 (0.4-8.6) 6.7 (3.9-13) 7.5 (5.5-33) 11 (1.5-22) 14 (5.7-28) 12 (4.6-24) 9.0 (2.9-21) 11 (2.1-43) 8.1 (2.5-27) 6.2 (2.2-22) 4.7 (1.7-25)
IgA2
1
Cases 63% 36% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL 0.04
(0-0.3)
<0.01
(<0.01-0.3)
0.7 (0.07-1.7) 1.3 (0.6-4.3) 1.5 (0.3-7.9) 2.5 (0.5-5.6) 2.5 (0.8-18) 3.2 (1.0-13) 2.7 (0.8-5.9) 4.1 (1.2-18) 3.6 (0.4-14) 3.4 (0.7-9.0) 2.5 (0.6-11)
PC subsets
IgM1
Cases 0% 79% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Cells/mL <0.01 0.3
(<0.01-2.9)
3.9 (0.3-12) 8.3 (4.8-52) 4.7 (1.1-8) 8.5 (0.6-40) 2.6 (0.6-7.2) 1.4 (0.6-14) 0.8 (0.2-5.7) 0.4 (0.05-4.7) 0.2 (0.04-1.0) 0.1
(0.01-0.8)
0.1
(0.02-1.1)
IgD1
Cases 0% 0% 0% 14% 50% 33% 84% 55% 36% 31% 19% 15% 17%
Cells/mL <0.01 <0.01 <0.01
(<0.01-0.2)
<0.01 (<0.01-0.7) <0.01
(<0.01-0.8)
<0.01
(<0.01-2.4)
0.3
(<0.01-2.3)
0.04
(<0.01-0.8)
<0.01
(<0.01-2.0)
<0.01 (<0.01-1.1) <0.01
(<0.01-0.1)
<0.01
(<0.01-0.2)
<0.01
(<0.01-0.02)
IgG1
1
Cases 0% 14% 100% 100% 100% 100% 100% 100% 100% 100% 93% 100% 92%
Cells/mL <0.01 <0.01
(<0.01-0.5)
4.5 (0.5-16) 10 (4.7-19.3) 8.5 (0.4-14) 8.5 (1.7-26) 3.3 (0.3-13) 1.9 (0.1-7.7) 1.1 (0.1-4.8) 0.4 (0.05-4.4) 0.2
(<0.01-1.7)
0.1
(0.01-0.6)
0.1
(<0.01-1.6)
(Continued)
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TABLE E4. (Continued)
CB
(n 5 19)
NB
(n 5 14)
1-5 mo
(n 5 11)
6-11 mo
(n 5 7)
12-17 mo
(n 5 12)
18-23 mo
(n 5 12)
2-4 y
(n 5 25)
5-9 y
(n 5 22)
10-17 y
(n 5 14)
18-39 y
(n 5 32)
40-59 y
(n 5 27)
60-79 y
(n 5 27)
>80 y
(n 5 12)
IgG2
1
Cases 0% 25% 82% 100% 75% 100% 100% 100% 100% 97% 96% 96% 100
Cells/mL <0.01 <0.01
(<0.01-0.1)
0.3
(<0.01-1.0)
1.1 (0.4-2.4) 0.3
(<0.01-2.4)
1.3 (1.3-4.7) 0.5 (0.02-1.5) 0.7
(0.07-2.3)
0.5 (0.08-0.8) 0.2 (<0.01-2.6) 0.2
(<0.01-0.7)
0.09
(<0.01-1.6)
0.1
(0.03-1.6)
IgG3
1
Cases 0% 0% 100% 100% 93% 92% 68% 76% 86% 59% 63% 27% 67%
Cells/mL <0.01 <0.01 0.2 (0.05-1.3) 0.7 (0.1-1.5) 0.6 (<0.01-3.4) 0.6
(<0.01-2.5)
0.1
(<0.01-2.1)
0.2
(<0.01-1.3)
0.08
(<0.01-0.4)
0.03 (<0.01-0.3) 0.02
(<0.01-0.2)
<0.01
(<0.01-0.2)
<0.01
(<0.01-0.23)
IgG4
1
Cases 0% 0% 9% 14% 48% 50% 20% 50% 43% 44% 30% 27% 33%
Cells/mL <0.01 <0.01 <0.01
(<0.01-0.15)
<0.01 (<0.01-0.1) <0.01
(<0.01-0.4)
<0.01
(<0.01-0.3)
<0.01
(<0.01-0.2)
0.02
(<0.01-0.2)
<0.01
(<0.01-0.2)
<0.01 (<0.01-0.4) <0.01
(<0.01-0.1)
<0.01
(<0.01-0.1)
<0.01
(<0.01-0.02)
IgA1
1
Cases 0% 14% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100
Cells/mL <0.01 <0.01
(<0.01-0.3)
6.1 (0.3-17) 17 (10-44) 9.6 (3.4-33) 10 (1.2-80) 7.3 (1.3-20) 4.4 (0.6-16) 3.1 (0.5-14) 1.7 (0.3-6.9) 0.9 (0.2-3.8) 0.4
(0.04-3.3)
0.6
(0.03-7.1)
IgA2
1
Cases 0% 7% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 92%
Cells/mL <0.01 <0.01
(<0.01-0.1)
1.2 (0.04-4.0) 2.8 (1.6-9.0) 1.6 (0.3-15) 2.6 (0.4-4.5) 1.1 (0.3-4.4) 1.5 (0.3-3.5) 1.0 (0.3-3.6) 0.7 (0.2-4.2) 0.3
(0.04-2.9)
0.3
(0.06-1.2)
0.2
(<0.01-1.2)
Results are expressed as percentages of cases and median absolute numbers of cells per microliter (range).
NB, Newborn.
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TABLE E5. Soluble plasma levels of different immunoglobulin isotypes and isotype subclasses through life
IgH isotypes/
subclasses
CB
(n 5 18)
NB
(n 5 10)
1-5 mo
(n 5 9)
6-11 mo
(n 5 7)
12-17 mo
(n 5 12)
18-23 mo
(n 5 12)
2-4 y
(n 5 25) 5-9 y (n 5 22)
10-17 y
(n 5 14)
18-39 y
(n 5 31)
40-59 y
(n 5 27)
60-79 y
(n 5 21)
>80 y
(n 5 11)
Total
immunoglobulin
748 (516-1484) 1108
(818-1223)
433 (267-634) 607 (377-915) 837
(542-1317)
866
(469-1092)
946
(596-1559)
1213
(814-1654)
1234
(686-1716)
1532
(1082-2182)
1430
(1073-1852)
1546
(978-1922)
1682
(1087-1804)
IgM 8.6 (<LOD-142) 15
(<LOD-23)
71
(<LOD-158)
52 (37-193) 59 (6-110) 82 (42-142) 89 (54-135) 89 (32-210) 75 (42-94) 107 (35-200) 104 (56-225) 84 (43-240) 79 (52-245)
IgD <LOD <LOD 0.3
(<LOD-0.7)
LOD
(<LOD-3.7)
0.4
(<LOD-3.1)
0.9
(<LOD-5.2)
1.8
(<LOD-22)
1.3 (<LOD-96) 0.7 (<LOD-6) 1.4
(<LOD-13)
1.1
(<LOD-5.9)
1.0
(<LOD-8.7)
0.4
(<LOD-1.4)
IgG1 560 (368-893) 833 (514-915) 241 (142-434) 424 (142-563) 506 (394-718) 628 (321-958) 616
(328-1200)
691 (459-942) 642 (405-931) 652
(390-1040)
592
(357-963)
657 (477-986) 649
(451-1100)
IgG2 187 (101-400) 200 (133-256) 75 (46-115) 50 (29-104) 62 (21-632) 108 (72-223) 102 (59-223) 186 (61-403) 240 (125-361) 370
(172-771)
377
(204-587)
377
(173-543)
336
(226-518)
IgG3 25 (12-66) 26 (15-36) 16 (9.6-38) 29 (20-70) 28 (21-236) 25 (12-58) 34 (11-86) 40 (20-74) 34 (21-72) 38 (11-86) 40 (23-188) 41 (20-96) 45 (24-85)
IgG4 34 (8-222) 34 (13-114) 9.0 (1.8-20) 1.8 (1.3-19) 22 (0.6-74) 8 (1.8-46) 13 (0.9-138) 38 (2.2-138) 56 (1.1-198) 92 (0.7-335) 45 (3.4-127) 46 (6.2-174) 55 (13-104)
IgA1 <LOD (<LOD-48) <LOD 13 (3.7-20.4) 23 (6.5-73) 27 (14-81) 31 (7-101) 52 (7-308) 87 (29-233) 146 (37-299) 138 (70-327) 139 (66-286) 156 (77-377) 214 (60-493)
IgA2 0.5 (<LOD-9) <LOD
(<LOD-0.6)
2.3 (0.7-7.2) 6.6 (0.7-7.7) 2.5 (1.0-11) 6.0 (2.6-35) 7.1 (1.4-39) 13 (1.0-35) 19 (7.1-44) 30 (11-131) 48 (14-80) 47 (14-122) 41 (25-114)
IgE <LOD <LOD <LOD
(<LOD-11)
<LOD
(<LOD-10)
14
(<LOD-202)
4.8
(<LOD-45)
16
(<LOD-102)
8.4
(<LOD-139)
33
(<LOD-444)
20
(<LOD-269)
22
(<LOD-45)
13
(<LOD-196)
28
(<LOD-105)
Results are expressed as medians (ranges). Total immunoglobulin and IgM, IgD, IgG, and IgA subclasses are expressed in milligrams per deciliter. IgE levels are expressed in international units per milliliter.
LOD, Limit of detection; NB, newborn.
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